Form 4: Maze Therapeutics President Sells Shares
Insider Transaction (Form 4)
Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., sold 16,142 shares of common stock on August 13, 2026 for $27.61 per share.
Summary
- Option exercise/conversion: acquired 16,142 Common Stock at $10.42 ($168,200) on August 13, 2026; holds 16,142 after (Direct).
- Open-market sale: disposed of 16,142 Common Stock at $27.61 ($445,621) on August 13, 2026 (Direct).
- Option exercise/conversion: disposed of 16,142 Stock Option (Right to Buy) on August 13, 2026; holds 176,803 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $445,621 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Harold Bernstein — Officer (President, R&D & CMO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-13 | Option exercise/conversion | Common Stock | 16,142 | $10 | $168.2K | 16,142 |
| 2026-08-13 | Open-market sale | Common Stock | 16,142 | $28 | $445.6K | 0 |
| 2026-08-13 | Option exercise/conversion | Stock Option (Right to Buy) | 16,142 | — | — | 176,803 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-13 | Option exercise/conversion (16,142 shares) |
| 2026-08-13 | Open-market sale (16,142 shares) |
| 2026-08-13 | Option exercise/conversion (16,142 shares) |
Keywords
insider transaction, Form 4, MAZE, Maze Therapeutics, Inc., bearish, Harold Bernstein
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.